MarketPulse
A

$AXSM

6 articles found
4 positive
0 negative
2 neutral
The Motley FoolThe Motley Fool··Jeff Siegel

Three AI-Powered Healthcare Firms Positioned to Disrupt Medicine by 2030

Three tech-driven companies—Tempus AI, Recursion Pharmaceuticals, and Axsome Therapeutics—are positioned to reshape healthcare through AI, precision medicine, and faster drug discovery by 2030.
AXSMRXRXTEMCNS disordersprecision medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Axsome Therapeutics Eyes Investor Spotlight with Back-to-Back Healthcare Conferences

Axsome Therapeutics to present at BofA Securities and RBC Capital Markets healthcare conferences in May 2026, with webcast access for remote investors.
AXSMFDA approvalinvestor conference
BenzingaBenzinga··Globe Newswire

Hypercharge Nets 2,700 Ports in Eddie Acquisition, Boosting Network 45%

Hypercharge Networks acquires Eddie EV charging network from AXSO, adding 2,700 ports and strengthening Quebec market presence through accretive, non-dilutive transaction.
AXSMacquisitionelectric vehicles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Axsome Therapeutics Schedules Q1 2026 Earnings Report for May 4

Axsome Therapeutics will report first-quarter 2026 financial results on May 4, 2026, with management conference call at 8:00 a.m. ET.
AXSMfinancial resultsclinical trials
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Two Biotech Stocks Poised to Outpace Summit Therapeutics Amid FDA Uncertainty

Summit Therapeutics faces FDA decision on ivonescimab by November 2026 amid efficacy concerns, while Axsome and Madrigal positioned for outperformance.
AXSMMDGLSMMTregulatory riskFDA approval
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials